Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today ...

Reusable catheter strategies may be as safe as single-use devices for preventing UTIs, but questions remain about their practical use.

Patient- and physician-facing interventions together doubled the reductions in PPI use ...

First Olmsted syndrome patient dosed in global Phase 1b studyCompany now operating under its new name, Orvida PharmaNESS ZIONA, Israel, April ...

The IMPACTS-BP trial showed that SPRINT-like reductions in systolic BP are possible even in tough real-world scenarios.

These collaborations represent a significant step forward in advancing embolotherapy for chronic musculoskeletal pain by combining world-class clinical expertise with a scalable outpatient care ...

Orvida Pharma (formerly Kamari Pharma), a privately held clinical-stage biotechnology company developing first and best-in-class treatments for rare and severe genetic skin diseases, today announced ...

Patients at high risk for pulmonary complications had similar support needs at 90 days with HFNOT or standard oxygen.

According to GLOBOCAN 2022, Vietnam records approximately 180,000 new cancer cases and over 120,000 deaths annually.

According to Verified Market Research®, the global Metabolomics Market Report was valued at USD 3.7 Billion in 2024 and is projected to reach USD 7.4 Billion by 2032, growing at a CAGR of 2.3% during ...

It couldn’t come at a better time, considering that cancer rates are rising among younger women.